India · Delayed Price · Currency is INR Marksans Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw record revenue and margin expansion, led by strong U.S. growth and stabilization in the U.K. New product launches, robust order book, and strategic expansion in Europe and Canada support a positive outlook, with INR 4,000 crore revenue targeted in 2-3 years.
-
Q2 FY 2026 delivered strong sequential and year-on-year growth, with revenue up 16% QoQ and 12.2% YoY, driven by robust U.S. and U.K. performance, new product launches, and operational efficiencies. Tariff uncertainties have eased, supporting a positive outlook and continued expansion in Europe.
-
Q1 FY26 saw 5% revenue growth and gross margin expansion, but profitability was impacted by one-time costs and UK price erosion. US business grew 30% year-on-year, while UK and Australia faced seasonal and pricing headwinds. Outlook remains cautious amid tariff uncertainties.
Fiscal Year 2025
-
Record revenue and profit growth in FY2025 was led by strong U.S. and OTC performance, with robust margins and a positive outlook for FY2026. Management expects to achieve INR 3,000 crore revenue, maintain healthy EBITDA margins, and continue product launches and expansion.
-
Q3 FY25 saw record PAT and 16.3% revenue growth, led by a 37% surge in U.S. sales. Gross margin expanded to 56.2%, while EBITDA margin dipped due to higher costs from facility ramp-up. Outlook remains strong with capacity and product pipeline supporting future growth.
-
Q2 FY25 delivered 20.8% revenue growth year-on-year, with record EBITDA and margin expansion driven by strong U.S. and Australia/NZ performance, Teva facility ramp-up, and lower raw material costs. Outlook remains positive with robust product launches and a target of INR 3,000 crores revenue in two years.
-
Q1 FY25 delivered robust revenue and profit growth, led by strong U.S. and U.K. performance, margin expansion, and successful ramp-up of the new facility. Freight costs remain a challenge, but management expects continued growth and targets INR 3,000 crore revenue in two years.